Related Experiment Videos
[Sensitivity of human tumor heterografts to a spin-labelled rubomycin derivative]
Abstract:
A degree of emoksil activity has been determined by applying the subrenal capsule assay methodology to fresh surgical explants of the normal immunocompetent mice. The ability of emoksil to inhibit growth of breast and colon tumours xenografts was determined. Emoksil substitution for adriamycin in the combination therapy increases the therapeutic activity. The kinetic criterion kappa calculated by the method of equivalent exponents was suggested to determine the tumour susceptibility to the drugs.
Insights
Emoksil demonstrated anti-tumor activity against breast and colon cancer xenografts in mice. Substituting emoksil for adriamycin enhanced combination therapy effectiveness, suggesting its potential in cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Experimental Medicine
Background:
- The subrenal capsule assay is a method for evaluating drug efficacy in vivo.
- Breast and colon tumors are significant global health concerns requiring novel therapeutic strategies.
- Adriamycin is a commonly used chemotherapy agent.
Purpose of the Study:
- To determine the anti-tumor activity of emoksil using the subrenal capsule assay.
- To evaluate emoksil's efficacy in inhibiting breast and colon tumor xenografts.
- To assess the impact of emoksil substitution for adriamycin in combination therapy.
Main Methods:
- Application of the subrenal capsule assay to fresh surgical explants from immunocompetent mice.
- Inhibition of breast and colon tumor xenograft growth was measured.
- The kinetic criterion kappa, calculated via equivalent exponents, was used to assess tumor susceptibility.
Main Results:
- Emoksil exhibited a degree of anti-tumor activity.
- Emoksil demonstrated the ability to inhibit the growth of breast and colon tumor xenografts.
- Replacing adriamycin with emoksil in combination therapy led to increased therapeutic activity.
Conclusions:
- Emoksil possesses anti-tumor properties against specific xenografts.
- Emoksil shows promise as a component in combination cancer therapy.
- The kinetic criterion kappa offers a method for predicting tumor drug susceptibility.